You searched for "specialist"
BCG after TURBT – does timing matter?
Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...
Disconnect between clinical trials and real-world oncology patients
Clinical trials are essential to advancing cancer treatment, providing the evidence needed to approve new therapies and improve patient outcomes. However, the strict eligibility criteria used – especially in prostate cancer trials – often exclude real-world patients. These criteria prioritise...Male infertility?
Diagnose Sperm Oxidative Stress, a major cause of male infertility, using MiOXSYS™
Multiparametric MRI with targeted-only biopsy – a new standard?
In this issue of European Urology, Kasivisvanathan et al. present a meta-analysis of two randomised trials comparing prebiopsy MRI with targeted biopsy (TBx) alone versus standard transrectal ultrasound-guided biopsy (TRUS-Bx) in biopsy-naïve men at risk of prostate cancer. Their findings...History of prostate biopsy – part 1
Part 2 of this topic is available here. Prostate biopsy (PBx) to exclude cancer has been part of clinical practice since the beginning of the 20th Century. PBx techniques have evolved over time to optimally address some of the unique...A guide to percutaneous nephrolithotomy
Percutaneous nephrolithotomy (PCNL) is now the gold standard approach to treating large renal stones. Since its development in the 1970s, it has undergone a series of refinements that could only have been possible with the symbiosis of both radiological and...
Sepsis – still a dilemma
Thousands of people die each year in the UK and worldwide due to types of sepsis, including urosepsis. Urologists are facing this scenario day in day out, so this is a vital article for every reader. We are all familiar...
Transurethral en bloc resection versus standard resection of bladder tumour
Bladder cancer is a common urological malignancy, with around 610,000 new cases and 220,000 deaths worldwide in 2022. Approximately 75% of these cases are non-muscle-invasive bladder cancer (NMIBC). The conventional method for treating NMIBC is standard resection (SR), performed transurethrally,...
